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Background: Current clinical practice guidelines recommend the use of prophylactic doses of low molecular
weight heparins for cancer patients requiring hospitalization for acute medical illness. However, a recently
published meta-analysis suggested that the risk-benefit ratio of current thromboprophylaxis regimens administered
to all cancer patients admitted for medical illness is unclear. We sought to assess the clinical equipoise in using
thromboprophylaxis for hospitalized medically ill cancer patients.
Methods: An electronic survey was conducted. The target sample included Thrombosis experts and members of
Thrombosis Canada or the VECTOR research group.
Results: The survey was distributed 54 participants. The final response rate was 67% (36/54). The majority (75%; 95%
CI: 60.3 to 85%) of responders indicated that the benefits of pharmacological parenteral thromboprophylaxis outweigh
the risks. However, 63.9% (95% CI: 50.6 to 77.3%) believe that there is still clinical equipoise around the use of
thromboprophylaxis in this patient population, and 88.9% (95% CI: 77.3 to 95.8%) would consider participating in
a randomized trial—30.6% and 58.3% in a placebo-controlled or comparison of different agents/dosing-controlled
randomized trial, respectively. For participants who would consider a randomized-controlled trial comparing
different doses of thromboprophylaxis agents, the MCID was 2% between the two arms. The most common drug
to be compared was enoxaparin (26%), and the two suggested doses were 30 mg and 40 mg SC twice daily.
Conclusions: Our clinical survey of thrombosis experts confirms that there is equipoise regarding the use of
current regimens of parenteral pharmacological thromboprophylaxis in medically ill cancer patients. A majority of
physicians would participate in a randomized-controlled trial comparing different dose of LMWH. The MCID in
the risk of VTE identified was 2%.Introduction
Venous thromboembolism (VTE) which includes both
pulmonary embolism (PE) and deep vein thrombosis
(DVT) is a frequent complication in cancer patients and
one of the leading causes of death in this population
[1,2]. The presence of cancer itself and the added risk of
hospitalization compound the risk of developing a VTE* Correspondence: mcarrier@toh.on.ca
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unless otherwise stated.[3]. Therefore, current clinical practice guidelines from
the American Society of Clinical Oncology, National
Comprehensive Cancer Network, the American College
of Chest Physicians (ACCP) and the European Society of
Medical Oncology all recommend the use of usual
prophylactic doses of low molecular weight heparins
(LMWH) for cancer patients requiring hospitalization for
acute medical illness in the absence of bleeding or other
contra-indications to anticoagulation [4-7]. These recom-
mendations are based on extrapolation from large ran-
domized controlled trials assessing the efficacy and safety
of pharmacological thromboprophylaxis in medically-ill
hospitalized patients [8-10]. However, a recently publishedral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,






Practicing for more than 10 years 60%
Practice in academic center 100%
Spent more than 50% of practice working with cancer related
VTE
17%
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gested that the risk-benefit ratio of current thromboprophy-
laxis regimens administered to all cancer patients admitted
for medical illness is unclear and additional randomized tri-
als are necessary to establish which cancer patients may
benefit from the routine administration of LMWH [11]. The
principal aim of this survey was to assess the clinical equi-
poise in using thromboprophylaxis for hospitalized
medically ill cancer patients and to evaluate the potential
participation in a future randomized controlled trial.
Methods
An Internet-based survey was conducted using Survey
Monkey. The target sample included Thrombosis ex-
perts and clinicians actively involved in the management
and prevention of thrombosis in adult patients—identi-
fied through Thrombosis Canada and VECTOR (VEnous
thromboembolism Clinical Trials and Outcomes Research)
member rosters. Thrombosis Canada is a Canadian regis-
tered non-profit organization with no commercial interests
dedicated to furthering education and research in the pre-
vention and treatment of thrombotic vascular disease.
Members include medical generalist and specialist that
have made significant contributions to the body of know-
ledge in vascular medicine (http://thrombosiscanada.ca/).
The VECTOR group is a large multi-centre collabora-
tive research group including 9 academic centers with a
focus on venous thromboembolism clinical trials and
studies. An email introducing the survey with the link
was initially distributed. Confidentiality was guaranteed
and participation in the survey was interpreted as con-
sent. A total of two reminders were also sent at 1-week
intervals. Prior to distribution, the survey was reviewed
by eight physicians (medical oncology, radiation oncol-
ogy, and thrombosis) at The Ottawa Hospital to ensure
validity and accuracy. The survey was conducted in mul-
tiple-choice format. General questions about pharmaco-
logical parenteral thromboprophylaxis in cancer patients,
use of established guidelines, risk/benefit ratio in this popu-
lation, and the clinical equipoise around the subject were
asked. Information was also collected regarding their will-
ingness in enrolling patients in a clinical trial, schedules,
doses, comparators, and minimal clinically important differ-
ence (MCID).
The results of the survey are stated using descriptive data
(percentages and 95% CI). Analytic comparisons were made
among relevant demographic subgroups regarding practice
patterns and willingness to conduct future trials of throm-
boprophylaxis in hospitalized cancer patients. Analyses
were conducted using Stats Direct software (version 2.7.9)
Results
The survey was distributed via email to 54 participants.
Following the initial email, two reminders over 1-weekintervals were sent and the final response rate was 67%
(36/54). The final sample consisted of hematologists
(68.6%), internists (25.7%), and medical oncologists (5.7%).
Baseline characteristics of the respondents are depicted in
Table 1. Of the participants, 57.1% were male and 60% had
been practicing for more than 10 years. All respondents
practiced in academic centers, and though 54.3% spent less
than 25% of their practice working with cancer related
VTE, 17% of the participants reported more than 50%.
Given the scenario of an adult patient with active cancer
(non-hematological malignancy) hospitalized for acute
medical illness (not due to surgery), who is neither actively
bleeding nor at high risk of bleeding, the majority of phy-
sicians (75%; 95% CI: 60.3 to 85%) would always recom-
mend the use of thromboprophylaxis. For this group of
patients, the majority (75%; 95% CI: 60.3-85%) of re-
sponders indicated that the benefits of pharmacological
parenteral thromboprophylaxis outweigh the risks. How-
ever, 63.9% (95% CI: 50.6 to 77.3%) believe that there is
still clinical equipoise around the use of thromboprophy-
laxis in this particular patient population, and 88.9% (95%
CI: 77.3 to 95.8%) would consider participating in a ran-
domized trial—30.6% and 58.3% in a placebo-controlled
or comparison of different agents/dosing-controlled ran-
domized trial, respectively. For those who would consider
a placebo-controlled trial, the absolute reduction in symp-
tomatic VTE reported as the MCID was 2% (63.6%) and
the absolute “acceptable” increase in major bleeding
events was 1% (63.6%). For participants who would con-
sider a randomized-controlled trial comparing different
doses of thromboprophylaxis agents, the MCID was 2%
between the two arms. The most common drug to be
compared was enoxaparin (26%), and the two suggested
doses were 30 mg and 40 mg SC twice daily.
Discussion
Our clinical survey of thrombosis experts confirms
that there is equipoise regarding the use of current
regimens of parenteral pharmacological thrombopro-
phylaxis in medically ill cancer patients. A majority of phy-
sicians would participate in a randomized-controlled trial
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risk of VTE identified was 2%.
As expected, the majority (75%) of participants recom-
mend thromboprophylaxis in adult patients with cancer
hospitalized for acute medical illness, and reported that the
risk of parenteral pharmacological thromboprophylaxis
outweighs the risk of bleeding in these patients. The ACCP
guidelines were the most frequently (87.9%) selected guide-
lines. The lack of evidence from randomized-controlled
trials supporting the efficacy of thromboprophylaxis is
generating significant clinical equipoise centered on the
dosing of parenteral pharmacological thromboprophylaxis
in this patient population.
A majority of clinicians (68%) selected LMWH as their
preferred pharmacological thromboprophylactic agent.
This is not surprising given that LMWH have a better
safety profile compared to unfractionated heparin. Unfrac-
tionated heparin (UFH) is easier to use, is associated with
higher risk of heparin-induced thrombocytopenia (1% for
UFH compared to 0.1% for LMWH) and is associated with
lower risk of a major bleeding among hospitalized medic-
ally ill patients [12]. Similarly, LMWH was preferred over
fondaparinux or the direct oral Factor Xa inhibitors (rivar-
oxaban or apixaban). Post-hoc analyses from randomized-
controlled trials comparing fondaparinux or rivaroxaban
with LMWH suggest that specific factor Xa inhibition
might be less efficacious than LMWH inhibition in cancer
patients [13,14]. The MAGELLAN trial assessed the effi-
cacy and safety of rivaroxaban in medically ill patients.
The supplemental data showed that patients with active
cancer randomized to 35 ± 4 days of rivaroxaban had
more asymptomatic proximal or symptomatic VTE than
patients receiving only 10 ± 4 days of enoxaparin (9.9%
(20/202) vs. 7.4% (15/203)) [13]. Although this difference
was not statistically significant due to the small number of
cancer patients enrolled, there was a statistically signifi-
cant increase in major and clinically relevant non-major
bleeding episodes with rivaroxaban compared with enoxa-
parin (5.4% vs. 1.7%). Therefore, parenteral pharmaco-
logical thromboprophylaxis using LMWH seems to be the
optimal choice.
When considering a randomized-controlled trial to de-
termine the optimal dose of LMWH, most of the partici-
pants favoured a trial assessing different doses of LMWH.
Enoxaparin has been shown to decrease D-dimer levels
and prothrombin fragments (F1 + 2) in hospitalized med-
ically ill patients [15,16]. Currently, a dose of 40 mg would
be the recommended dose in these patients. Higher doses
of enoxaparin (80 mg) have been reported to significantly
decrease the peak thrombin levels compared to the lower
dose (40 mg) in hospitalized cancer patients, suggesting
that the pro-thrombotic state related to cancer might be
attenuated by higher doses of LMWH [16]. Previous clin-
ical studies in other high-risk cancer populations assessingthe use of higher doses of LMWH have also demonstrated
significant benefits without increasing the risk of bleeding
[17-19]. Therefore, assessing different doses of LMWH
has a strong biological and clinical rational.
It is important to acknowledge the limitations of our sur-
vey. The target sample size was relatively small which might
introduce selection bias. However, the response rate was
high and it is important to emphasize that the survey tar-
geted thrombosis experts only in order to provide the most
relevant opinions regarding the assessment of the MCID.
In addition, the sample size was limited to Canadian clini-
cians from academic centers, and therefore, may not reflect
the worldwide opinion on the topic.
In conclusion, our survey shows that there is clinical
equipoise regarding the use of pharmacological thrombo-
prophylaxis in medically ill cancer patients, and calls for
trials comparing different doses of thromboprophylaxis in
these patients.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PM, Designed, performed research; collected, analyzed, interpreted data;
statistical analysis; wrote manuscript. MC, Designed, performed research;
collected, analyzed, interpreted data; statistical analysis; wrote manuscript.
JP, Interpreted data; wrote manuscript. MR, Analyzed and interpreted data;
provided vital reviews to the manuscript. GL, Analyzed and interpreted data;
provided vital reviews to the manuscript. All authors read and approved the
final manuscript.
Acknowledgements
MC is a recipient of a New Investigator Award from the Heart and Stroke
Foundation of Canada and a T2 Research Chair in Venous
Thromboembolism from the University of Ottawa. MR is a Career Scientist of
the Heart and Stroke Foundation of Ontario, a Faculty of Medicine and
Department of Medicine Clinical Research Chair and is also the recipient of
the Ministry of Research and Innovation’s Early Researcher Award. GLG is the
recipient of the Ministry of Research and Innovation’s Early Researcher Award
Author details
1Kaplan Instituto de Oncologia, Porto Alegre, Rio Grande do Sul, Brazil.
2Department of Medicine, The Ottawa Hospital Research Institute, University
of Ottawa, 501 Smyth Road, Box 201A, Ottawa, ON, Canada. 3Institut de
Recherche de l’Hôpital Montfort, University of Ottawa, Ottawa, Canada.
Received: 22 December 2014 Accepted: 3 February 2015
References
1. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with
cancer: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001275.
2. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency,
risk factors, and trends for venous thromboembolism among hospitalized
cancer patients. Cancer. 2007;110:2339–46.
3. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton III LJ.
Risk factors for deep vein thrombosis and pulmonary embolism: a
population-based case–control study. Arch Intern Med. 2000;160:809–15.
4. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al.
Venous thromboembolism prophylaxis and treatment in patients with
cancer: American Society of Clinical Oncology clinical practice guideline
update. J Clin Oncol. 2013;31:2189–204.
5. National Comprehensive Cancer Network. Clinical Practice Guidelines in
Oncology Venous Thromboembolic Disease version 2. 2011. Accessed Jan
10, 2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.
asp#supportive. National Comprehensive Cancer Network . 2012.
Moretto et al. Thrombosis Journal  (2015) 13:10 Page 4 of 46. Mandala M, Falanga A, Roila F. Management of venous thromboembolism in
cancer patients: ESMO clinical recommendations. Ann Oncol. 2008;19:ii126–7.
7. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention
of VTE in nonsurgical patients: antithrombotic therapy and prevention of
thrombosis, 9th ed: American College of Chest Physicians evidence-based
clinical practice guidelines. Chest. 2012;141:e195S–226S.
8. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al.
Efficacy and safety of fondaparinux for the prevention of venous
thromboembolism in older acute medical patients: randomised placebo
controlled trial. BMJ. 2006;332:325–9.
9. Leizorovicz A, Cohen AT, Turpie AGG, Olsson CG, Vaitkus PT, Goldhaber SZ.
Randomized, placebo-controlled trial of Dalteparin for the prevention of
venous thromboembolism in acutely ill medical patients. Circulation.
2004;110:874–9.
10. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al.
A comparison of enoxaparin with placebo for the prevention of venous
thromboembolism in acutely ill medical patients. Prophylaxis in Medical
Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793–800.
11. Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI. Lack of
evidence to support thromboprophylaxis in hospitalized medical patients
with cancer. Am J Med. 2014;127:82–6.
12. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A,
Juillard-Delsart D, et al. Prevention of venous thromboembolism in
internal medicine with unfractionated or low-molecular-weight heparins: a
meta-analysis of randomised clinical trials. Thromb Haemost. 2000;83:14–9.
13. Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D, Hull R, et al. Rivaroxaban for
thromboprophylaxis in acutely ill medical patients. N Engl J Med.
2013;368:513–23.
14. van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing
AW, et al. Treatment of venous thromboembolism in patients with cancer:
Subgroup analysis of the Matisse clinical trials. Thromb Haemost.
2009;101:762–9.
15. Traby L, Kaider A, Schmid R, Kranz A, Quehenberger P, Kyrle PA, et al.
The effects of low-molecular-weight heparin at two different dosages on
thrombin generation in cancer patients. A randomised controlled trial.
Thromb Haemost. 2010;104:92–9.
16. Desjardins L, Bara L, Boutitie F, Samama MM, Cohen AT, Combe S, et al.
Correlation of plasma coagulation parameters with thromboprophylaxis,
patient characteristics, and outcome in the MEDENOX study. Arch Pathol
Lab Med. 2004;128:519–26.
17. Riess H, Pelzer U, Deutschinoff G, Opitz B, Stauch M, Reitzig P, et al. A
prospective, randomized trial of chemotherapy with or without the low
molecular weight heparin (LMWH) enoxaparin in patients (pts) with
advanced pancreatic cancer (APC): Results of the CONKO 004 trial. J Clin
Oncol. 2009;27:abstract LBA4506.
18. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L, et al.
Nadroparin for the prevention of thromboembolic events in ambulatory
patients with metastatic or locally advanced solid cancer receiving
chemotherapy: a randomised, placebo-controlled, double-blind study.
Lancet Oncol. 2009;10:943–9.
19. Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, et al. Gemcitabine
versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic
cancer. Eur J Cancer. 2012;48:1283–92.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
